1
|
Chen C, Zhang E, Zhu C, Wei R, Ma L, Dong X, Li R, Sun F, Zhou Y, Cui Y, Liu Z. Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis. J Am Pharm Assoc (2003) 2023; 63:8-22.e23. [PMID: 36055929 DOI: 10.1016/j.japh.2022.07.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 07/20/2022] [Accepted: 07/21/2022] [Indexed: 01/25/2023]
Abstract
BACKGROUND Currently, 19 disease-modifying therapies (DMTs) have been approved for the treatment of patients with relapsing forms of multiple sclerosis (RMS). OBJECTIVE The objective of this study was to conduct a systematic review and network meta-analysis to evaluate the efficacy and safety of DMTs in adults with RMS. METHODS We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, the Food and Drug Administration, and European Medicines Agency websites for randomized controlled trials (RCTs) (from inception to July 2021). Eligible RCTs evaluated approved treatments for RMS as monotherapy and reported at least one of the primary outcome measures of interest. The primary outcome was efficacy (annualized relapse rate and 12-week confirmed disability progression) and safety (serious adverse events [AEs] and discontinuation due to AEs). We assessed the risk of bias (RoB) of included studies using the Cochrane RoB tool version 2.0 (https://www.bmj.com/content/343/bmj.d5928) for RCTs. Surface under the cumulative ranking (SUCRA) was used to rank therapies and to assess quality of general evidence, respectively. The Grading of Recommendations Assessment, Development and Evaluation framework was used to rank therapies and to assess quality of general evidence. RESULTS A total of 43 records represent 45 RCTs selected for network meta-analysis. In total, 30,720 participants (median of 732; interquartile range: 248-931) were included, of which 67% were female. By SUCRA analysis, alemtuzumab (94.3%) presented the highest probability of being the best alternative for annualized relapse rate, whereas ofatumumab (93.5%) presented the highest probability of being the best alternative for 12-week confirmed disability progression. Interferon beta-1b subcutaneous (87.0%) presented the highest probability of the best safety among all DMTs for serious AEs, whereas alemtuzumab (92.4%) presented the highest probability of the best safety among all DMTs for discontinuation due to AEs. CONCLUSION Network meta-analysis shows that alemtuzumab and ofatumumab present the highest efficacy among DMTs. Because there is little difference between these probabilities for many treatments, health professionals should use clinical shared decision making when formulating treatment plans with patients.
Collapse
|
2
|
Aybek S, Chan A. The borderland of multiple sclerosis and functional neurological disorder: A call for clinical research and vigilance. Eur J Neurol 2023; 30:3-8. [PMID: 36135345 DOI: 10.1111/ene.15568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Revised: 07/29/2022] [Accepted: 08/12/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND PURPOSE Functional neurological disorders (FNDs) have attracted much attention from the neurological medical community over the last decades as new developments in neurosciences have reduced stigma around these by showing brain network dysfunctions. An overlap with other neurological conditions such as multiple sclerosis (MS) is well known by clinicians but there is a lack of clinical and fundamental research in this field to better define diagnosis and therapeutic decisions, as well as a lack of deep understanding of the underlying pathophysiology. AIM We aimed to provide a critical commentary on the state of knowledge about the borderland between FNDs and MS. METHODS We based our commentary on a joint point of view between an FND specialist and an MS expert. RESULTS A brief review of the previous literature and relevant new studies covering the overlap between FNDs and MS is presented, along with suggestions for future research directions. CONCLUSION There are clear diagnostic criteria for both FNDs and MS and a strict application of these will help better diagnosis and prevent unnecessary treatment escalation in MS or absence of referral to multimodal therapy in FND. Better teaching of younger neurologists is needed as well as prospective research focusing on pathophysiology.
Collapse
Affiliation(s)
- Selma Aybek
- Psychosomatic Medicine Unit, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Andrew Chan
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| |
Collapse
|
3
|
Marco-Martín G, Tornero P, Prieto A, La Rotta A, Herrero T, Baeza ML. Immediate reactions with glatiramer acetate: Diagnosis of allergy and desensitization protocols. Neurol Clin Pract 2020; 10:170-177. [PMID: 32309036 DOI: 10.1212/cpj.0000000000000714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Accepted: 05/29/2019] [Indexed: 11/15/2022]
Abstract
Purpose of review Diverse adverse events have been associated with administration of glatiramer acetate (GA), mainly local reactions at the injection site. Other, less frequent generalized reactions include isolated postinjection reactions and anaphylaxis, which may lead to discontinuation of GA. Recent findings Close collaboration between the allergy and neurology departments is needed to study adverse reactions to GA. The allergy study should include a detailed history and skin prick and intradermal tests with GA and, if possible, determination of specific IgE levels. Furthermore, the implication of other drugs should be ruled out. Summary An accurate diagnosis of reactions to GA is essential if we are to confirm or rule out allergy to GA. When an allergy diagnosis is confirmed or firmly suspected based on clinical evidence, desensitization protocols are increasingly seen as safe methods for reintroduction of GA.
Collapse
Affiliation(s)
- Guadalupe Marco-Martín
- Allergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Pilar Tornero
- Allergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Alicia Prieto
- Allergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Alejandro La Rotta
- Allergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Teresa Herrero
- Allergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Maria Luisa Baeza
- Allergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain
| |
Collapse
|
4
|
Tabansky I, Messina MD, Bangeranye C, Goldstein J, Blitz-Shabbir KM, Machado S, Jeganathan V, Wright P, Najjar S, Cao Y, Sands W, Keskin DB, Stern JNH. Advancing drug delivery systems for the treatment of multiple sclerosis. Immunol Res 2016; 63:58-69. [PMID: 26475738 DOI: 10.1007/s12026-015-8719-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. It is characterized by demyelination of neurons and loss of neuronal axons and oligodendrocytes. In MS, auto-reactive T cells and B cells cross the blood-brain barrier (BBB), causing perivenous demyelinating lesions that form multiple discrete inflammatory demyelinated plaques located primarily in the white matter. In chronic MS, cortical demyelination and progressive axonal transections develop. Treatment for MS can be stratified into disease-modifying therapies (DMTs) and symptomatic therapy. DMTs aim to decrease circulating immune cells or to prevent these cells from crossing the BBB and reduce the inflammatory response. There are currently 10 DMTs approved for the relapsing forms of MS; these vary with regard to their efficacy, route and frequency of administration, adverse effects, and toxicity profile. Better drug delivery systems are being developed in order to decrease adverse effects, increase drug efficacy, and increase patient compliance through the direct targeting of pathologic cells. Here, we address the uses and benefits of advanced drug delivery systems, including nanoparticles, microparticles, fusion antibodies, and liposomal formulations. By altering the properties of therapeutic particles and enhancing targeting, breakthrough drug delivery technologies potentially applicable to multiple disease treatments may rapidly emerge.
Collapse
Affiliation(s)
- Inna Tabansky
- Department of Neurobiology and Behavior, The Rockefeller University, New York, NY, USA
| | - Mark D Messina
- Department of Neurology, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA.,Department of Science Education, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
| | - Catherine Bangeranye
- Department of Science Education, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
| | - Jeffrey Goldstein
- Department of Neurology, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA.,Department of Science Education, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
| | - Karen M Blitz-Shabbir
- Department of Neurology, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
| | - Suly Machado
- Department of Neurology, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA.,Department of Science Education, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
| | - Venkatesh Jeganathan
- Department of Autoimmunity, The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY, USA
| | - Paul Wright
- Department of Neurology, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
| | - Souhel Najjar
- Department of Neurology, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
| | - Yonghao Cao
- Department of Autoimmunity, The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY, USA
| | - Warren Sands
- School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.,Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Derin B Keskin
- Department of Cancer Immunology and AIDS, Dana Farber-Harvard Cancer Institute, Boston, MA, USA
| | - Joel N H Stern
- Department of Neurobiology and Behavior, The Rockefeller University, New York, NY, USA. .,Department of Neurology, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA. .,Department of Science Education, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA. .,Department of Autoimmunity, The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY, USA.
| |
Collapse
|
5
|
Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014; 89:225-40. [PMID: 24485135 DOI: 10.1016/j.mayocp.2013.11.002] [Citation(s) in RCA: 292] [Impact Index Per Article: 29.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2013] [Revised: 11/01/2013] [Accepted: 11/07/2013] [Indexed: 12/20/2022]
Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system disease that typically strikes young adults, especially women. The pathobiology of MS includes inflammatory and neurodegenerative mechanisms that affect both white and gray matter. These mechanisms underlie the relapsing, and often eventually progressive, course of MS, which is heterogeneous; confident prediction of long-term individual prognosis is not yet possible. However, because revised MS diagnostic criteria that incorporate neuroimaging data facilitate early diagnosis, most patients are faced with making important long-term treatment decisions, most notably the use and selection of disease-modifying therapy (DMT). Currently, there are 10 approved MS DMTs with varying degrees of efficacy for reducing relapse risk and preserving neurological function, but their long-term benefits remain unclear. Moreover, available DMTs differ with respect to the route and frequency of administration, tolerability and likelihood of treatment adherence, common adverse effects, risk of major toxicity, and pregnancy-related risks. Thorough understanding of the benefit-risk profiles of these therapies is necessary to establish logical and safe treatment plans for individuals with MS. We review the available evidence supporting risk-benefit profiles for available and emerging DMTs. We also assess the place of individual DMTs within the context of several different MS management strategies, including those currently in use (sequential monotherapy, escalation therapy, and induction and maintenance therapy) and others that may soon become feasible (combination approaches and "personalized medicine"). We conducted this review using a comprehensive search of MEDLINE, PubMed, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials, from January 1, 1990, to August 31, 2013. The following search terms were used: multiple sclerosis, randomized controlled trials, interferon-beta, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, BG-12, alemtuzumab, rituximab, ocrelizumab, daclizumab, neutralizing antibodies, progressive multifocal leukoencephalopathy.
Collapse
|
6
|
Prosperini L, Mancinelli CR, Pozzilli C, Grasso MG, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, Buttari F, Centonze D, Di Battista G, Frisullo G, Galgani S, Gasperini C. From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. Eur Neurol 2014; 71:233-41. [DOI: 10.1159/000356786] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2013] [Accepted: 10/27/2013] [Indexed: 11/19/2022]
|
7
|
Stewart TM, Tran ZV. Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions. Int J MS Care 2014; 14:46-53. [PMID: 24453732 DOI: 10.7224/1537-2073-14.1.46] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Although injection-site reactions (ISRs) occur with US Food and Drug Administration-approved injectable disease-modifying therapies (DMTs) for multiple sclerosis, there are currently few reports of real-world data on ISR management strategies or possible correlations between ISRs and patient demographics, disease characteristics, and missed injections. Patient-reported data on the use of DMTs, patient demographic and disease characteristics, missed injections, and ISR reduction strategies were collected via e-mail, a patient registry (www.ms-cam.org), and a Web-based survey. Of the 1380 respondents, 1201 (87%) indicated that they had used injectable DMTs, of whom 377 (31%) had used intramuscular (IM) interferon beta-1a (IFNβ-1a), 172 (14%) had used subcutaneous (SC) IFNβ-1a, 183 (15%) had used SC IFNβ-1b, and 469 (39%) had used glatiramer acetate (GA). The majority of respondents were older (73% were ≥40 years), female (79%), married or living with a partner (72%), white (94%), and nonsmoking (82%). Injection-site reaction incidence, grouped according to severity, varied among DMTs, with IM IFNβ-1a causing significantly (P < .001) fewer mild, moderate, or severe ISRs than the other therapies. Female sex and younger age were significantly (P < .05) associated with more moderate ISRs among users of IM IFNβ-1a, SC IFNβ-1b, and GA. Nonwhites reported severe ISRs more often than whites. For all DMTs injection-site massage and avoidance of sensitive sites were the most frequently used strategies to minimize ISRs. These data may help identify patients with characteristics associated with a higher risk for ISRs, allowing health-care professionals to provide anticipatory guidance to patients at risk for decreased adherence or discontinuation.
Collapse
Affiliation(s)
- Thomas M Stewart
- Rocky Mountain MS Center, Westminster, CO, USA (TMS), and the Department of Biostatistics & Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA (ZVT)
| | - Zung Vu Tran
- Rocky Mountain MS Center, Westminster, CO, USA (TMS), and the Department of Biostatistics & Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA (ZVT)
| |
Collapse
|
8
|
Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol 2013; 70:1315-24. [PMID: 23921521 PMCID: PMC4106803 DOI: 10.1001/jamaneurol.2013.3510] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Several innovative disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis have been licensed recently or are in late-stage development. The molecular targets of several of these DMTs are well defined. All affect at least 1 of 4 properties, namely (1) trafficking, (2) survival, (3) function, or (4) proliferation. In contrast to β-interferons and glatiramer acetate, the first-generation DMTs, several newer therapies are imbued with safety issues, which may be attributed to their structure or metabolism. In addition to efficacy, understanding the relationship between the mechanism of action of the DMTs and their safety profile is pertinent for decision making and patient care. In this article, we focus primarily on the safety of DMTs in the context of understanding their pharmacological characteristics, including molecular targets, mechanism of action, chemical structure, and metabolism. While understanding mechanisms underlying DMT toxicities is incomplete, it is important to further develop this knowledge to minimize risk to patients and to ensure future therapies have the most advantageous benefit-risk profiles. Recognizing the individual classes of DMTs described here may be valuable when considering use of such agents sequentially or possibly in combination.
Collapse
|
9
|
Gasperini C, Ruggieri S, Pozzilli C. Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets. Ther Clin Risk Manag 2010; 6:391-9. [PMID: 20856685 PMCID: PMC2940747 DOI: 10.2147/tcrm.s6639] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2010] [Indexed: 11/26/2022] Open
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) that represents one of the first causes of neurological disability in young adults. Although the pathogenesis of MS is still unclear, an autoimmune mechanism has been demonstrated. According to this evidence in the last 15 years different treatments acting on the immune system have been developed. Current disease-modifying drugs (DMDs) for MS require regular and frequent parenteral administration and are associated with limited long-term treatment adherence. Moreover the clinical efficacy of these disease-modifying drugs is suboptimal. Thus, there is an important need for the development of new therapeutic strategies. Several oral therapies (fingolimod, fumaric acid, teriflunomide, laquinimod) are in development; Among these cladribine is the only therapy with the potential for short-course dosing. Cladribine is an immunosuppressant that offers sustained regulation of the immune system through a preferential lymphocyte depleting action. Cladribine has a well-characterized and well-known safety profile, derived from more than 15 years of use of the parenteral formulation both in the oncology field and in MS. This paper reviews the new oral emerging treatments and presents the available data about the use of cladribine in MS and the future perspective of its clinical use.
Collapse
Affiliation(s)
- Claudio Gasperini
- Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy
| | | | | |
Collapse
|
10
|
Effect of Oral Antihistamine on Local Injection Site Reactions With Self-Administered Glatiramer Acetate. J Neurosci Nurs 2010; 42:40-6. [DOI: 10.1097/jnn.0b013e3181c71ab7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Bellomi F, Bramanti P, Trojano M, Scagnolari C, Muto A, Sessa E, La Volpe V, Russo P, Antonelli G. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres. J Immunoassay Immunochem 2009; 30:40-50. [PMID: 19117201 DOI: 10.1080/15321810802569857] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in a percentage of patients. This study investigated the reproducibility of results of two different antibody detection techniques using serum from 100 patients with MS who were receiving IFN beta therapy. Fifty samples were analysed using a commercially available kit-based BAb assay and a further 50 different samples were analysed using a widely used NAb cytopathic effect assay, at three different laboratories. All three centres agreed on the BAb status of all serum samples. However, only 84% agreement was reached on serum NAb status, and there was significant inter-laboratory variation in NAb titre values. Further analysis of these data revealed a correlation between the mean NAb titre and the coefficient of variation of serum samples, indicating greater discordance with higher NAb titres. A significant interlaboratory variation in NAb titres does exist; thus, caution is required when comparing titres from different centres. It is clear that validated detection assays are needed to accurately quantify NAb titres.
Collapse
Affiliation(s)
- Francesca Bellomi
- Department of Experimental Medicine - Virology Section, University La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Sternberg Z, Chadha K, Lieberman A, Hojnacki D, Drake A, Zamboni P, Rocco P, Grazioli E, Weinstock-Guttman B, Munschauer F. Quercetin and interferon-β modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol 2008; 205:142-7. [DOI: 10.1016/j.jneuroim.2008.09.008] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2008] [Revised: 08/27/2008] [Accepted: 09/05/2008] [Indexed: 11/30/2022]
|
13
|
|
14
|
Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007; 23:2667-76. [PMID: 17880754 DOI: 10.1185/030079907x233142] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Disease-modifying drugs available for multiple sclerosis (MS) require chronic, regular, parenteral administration. Effective oral MS therapies may improve long-term adherence. A number of oral therapies are in development, including cladribine--a preferential lymphocyte-depleting therapy with a well-established safety profile across other indications. OBJECTIVE To review information available on the safety and efficacy of cladribine in the treatment of MS, in the context of the ongoing development of an oral tablet formulation. METHODS An electronic search was performed to identify publications in which 'cladribine' was listed as a major index term. Results of the literature search were supplemented by other relevant secondary references and publications. FINDINGS The majority of published data on cladribine describe its use in diseases other than MS. However, three major, industry-sponsored, double-blind, placebo-controlled trials of parenteral cladribine were identified, involving 262 patients with relapsing or progressive forms of MS. Patients received cumulative doses of 0.7-2.8 mg/kg of cladribine over 4-6 months and were followed-up for at least 6-12 months thereafter. Individual results of these studies of parenteral cladribine indicate that it can reduce: (i) the number and volume of T1 gadolinium-enhancing lesions; (ii) the accumulation of T2 lesion volume; (iii) relapse rate; and (iv) disability progression. A dose-dependent increase in adverse events was observed, leading to selection of low doses for use in an ongoing clinical development program of an oral tablet formulation. Efficacy and safety data from four independent studies/case reports have also supported the potential benefits of cladribine in MS. While parenteral cladribine (at doses of 0.7-2.1 mg/kg) is associated with a good short-term safety and tolerability profile, additional long-term data are required--and the safety profile of the oral tablet formulation is yet to be established. To this end, the efficacy and safety of oral cladribine tablets are now being assessed as monotherapy and add-on therapy to interferon-beta-1a in two, 96-week, double-blind clinical trials of relapsing forms of MS. These ongoing studies will utilize newer diagnostic criteria and more sensitive evaluation techniques than were available at the time of the parenteral studies of cladribine. CONCLUSION Preliminary data indicate that cladribine is effective for the treatment of MS and has a promising safety and tolerability profile. The sustained immunologic effects of cladribine make it suitable for intermittent oral dosing, which is expected to offer benefits for patient satisfaction and therapeutic adherence.
Collapse
|
15
|
Kremenchutzky M, Morrow S, Rush C. The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. Expert Opin Drug Saf 2007; 6:279-88. [PMID: 17480177 DOI: 10.1517/14740338.6.3.279] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Multiple sclerosis, a chronic demyelinating disease of the CNS, is now a treatable disease. Phase III clinical trials of three recombinant IFN-beta products conducted in relapsing-remitting multiple sclerosis have shown, albeit modest, significant effects on relapses and short-term progression of disability, and a more substantial effect on MRI parameters. However, these effects do not correlate well with clinical disease activity or long-term disability. Overall, IFN-beta is safe and generally well tolerated, and reported adverse events were comparable between preparations. Systemic side effects can be effectively managed by dose escalation, use of an auto-injector and careful clinical monitoring.
Collapse
Affiliation(s)
- Marcelo Kremenchutzky
- University of Western Ontario, Department of Clinical Neurological Sciences, London Health Sciences Centre, Canada
| | | | | |
Collapse
|